By Ian Walker


Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the company's denosumab biosimilars products, paving the way for it to launch its bone treatments Jubbonti and Wyost in the U.S. by May 31.

The Swiss pharmaceutical company didn't disclose any terms of the agreement but said it doesn't impact previously disclosed guidance for this year. It said on March 31 that the company expects 2024 net sales to grow mid-single digit in constant currencies.

Sandoz received U.S. Food and Drug Administration approval for Wyost and Jubbonti--the first denosumab biosimilars to treat skeletal-related events and osteoporosis--on March 5.


Write to Ian Walker at ian.walker@wsj.com


(END) Dow Jones Newswires

04-30-24 0202ET